Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.
Richtig G, Richtig M, Hoetzenecker W, Saxinger W, Lange-Asschenfeldt B, Steiner A, Strohal R, Posch C, Bauer JW, Müllegger RR, Deinlein T, Sepp N, Volc-Platzer B, Nguyen VA, Schmuth M, Hoeller C, Pregartner G, Richtig E. Richtig G, et al. Among authors: hoeller c. Acta Derm Venereol. 2019 Jan 1;99(1):58-62. doi: 10.2340/00015555-3037. Acta Derm Venereol. 2019. PMID: 30206639 Free article.
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. Among authors: hoeller c. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.
Lang R, Welponer T, Richtig E, Wolf I, Hoeller C, Hafner C, Nguyen VA, Kofler J, Barta M, Koelblinger P, Hitzl W, Emberger M, Laimer M. Lang R, et al. Among authors: hoeller c. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1799-1810. doi: 10.1111/jdv.19218. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37210651 Clinical Trial.
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E, Nguyen VA, Koelblinger P, Wolf I, Kehrer H, Saxinger W, Ressler JM, Weinlich G, Meyersburg D, Hafner C, Jecel-Grill E, Kofler J, Lange-Asschenfeldt B, Weihsengruber F, Rappersberger K, Svastics N, Gasser K, Seeber A, Kratochvill F, Nagler S, Mraz B, Hoeller C. Richtig E, et al. Among authors: hoeller c. Melanoma Res. 2024 Apr 1;34(2):142-151. doi: 10.1097/CMR.0000000000000948. Epub 2023 Dec 13. Melanoma Res. 2024. PMID: 38092013 Free PMC article.
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. Carlino MS, et al. Among authors: hoeller c. Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7. Eur J Cancer. 2018. PMID: 30096704 Free article. Clinical Trial.
85 results